Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Received FDA clearance of IND application for brain-penetrant MEK inhibitor, KIN-7136; expect to enter the clinic with Phase 1 trial in the second half of 2023Cash, cash equivalents and investments of...
Source: marketscreener.com